The Epigenetic Promise to Improve Prognosis of Heart Failure and Heart Transplantation

Heart transplantation (HT) remains the gold standard treatment for end-stage heart failure (HF) ensuring the highest long-term survival; however, due to the shortage of organ donors, the left ventricular assist device (LVAD) provides a backup strategy for patients as bridge to transplantation or when clinical contraindications are present [1,2]. HF represents the end-stage of several cardiac pathological conditions including atherosclerosis, coronary heart disease (CHD) and dilated, hypertrophic and restrictive cardiomyopathies [3-5].
Source: Transplantation Reviews - Category: Transplant Surgery Authors: Tags: Review article Source Type: research